REGENERON PHARMACEUTICALS financial statements, including revenue, expenses, profit, and loss
The total revenue of 4REGN for the last quarter is 3.31 B EUR, and it's 13.62% higher compared to the previous quarter. The net income of Q2 24 is 1.34 B EUR.